专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018078053A1 LIPID NANOPARTICLE MRNA VACCINES 审中-公开
标题翻译：脂质纳米颗粒MRNA疫苗
公开(公告)号：WO2018078053A1
公开(公告)日：2018-05-03
申请号：PCT/EP2017/077517
申请日：2017-10-26
申请人： CUREVAC AG , ACUITAS THERAPEUTICS INC.
发明人： BAUMHOF, Patrick , FOTIN-MLECZEK, Mariola , HEIDENREICH, Regina , HOPE, Michael J. , JASNY, Edith , LAZZARO, Sandra , LIN, Paulo Jia Ching , LUTZ, Johannes , MUI, Barbara , PETSCH, Benjamin , RAUCH, Susanne , SCHMIDT, Kim Ellen , TAM, Ying
IPC分类号： A61K39/12 , A61K39/39 , A61P31/16 , A61P31/14 , A61K9/51 , A61K31/225 , A61K9/16 , A61K47/18 , A61K9/127 , C07C219/06 , C07C229/16 , C07C233/18 , C07C255/24
摘要： The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.
摘要翻译：本发明涉及包含脂质纳米颗粒的mRNA及其医学用途。本发明的脂质纳米颗粒包含根据式（I），（II）或（III）的阳离子脂质和/或根据式（IV）的PEG脂质，以及包含编码抗原肽或蛋白质。本发明进一步涉及所述脂质纳米颗粒作为疫苗或药物的用途，特别是关于流感或狂犬病疫苗。

2. 发明申请

WO2020002525A1 NOVEL LASSA VIRUS RNA MOLECULES AND COMPOSITIONS FOR VACCINATION 审中-公开
公开(公告)号：WO2020002525A1
公开(公告)日：2020-01-02
申请号：PCT/EP2019/067205
申请日：2019-06-27
申请人： CUREVAC AG
发明人： JASNY, Edith , PETSCH, Benjamin , GROSSE, Hans Wolfgang
IPC分类号： A61K39/12 , C12N7/00
摘要： The present invention is directed to RNA suitable for use in treatment and/or prophylaxis of an infection with Lassa virus (LASV) or of a disorder related to such an infection. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the RNA, compositions, and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the RNA, compositions and vaccines.

3. 发明申请

WO2018115525A1 LASSA VIRUS VACCINE 审中-公开
公开(公告)号：WO2018115525A1
公开(公告)日：2018-06-28
申请号：PCT/EP2017/084562
申请日：2017-12-22
申请人： CUREVAC AG
发明人： JASNY, Edith , PETSCH, Benjamin
IPC分类号： A61K39/12 , C12N7/00 , A61P31/14
摘要： The present invention provides mRNAs usable as vaccines against lassa virus (LASV) infections. Further, the invention relates to (pharmaceutical) compositions and vaccines comprising said mRNAs and their use for treatment or prophylaxis of a lassa virus infection. The present invention further features a kit comprising the mRNAs, (pharmaceutical) compositions or vaccines and a method for treatment or prophylaxis of lassa virus infections using said mRNAs, pharmaceutical) compositions or vaccines.

4. 发明申请

WO2016097065A1 EBOLAVIRUS AND MARBURGVIRUS VACCINES 审中-公开
标题翻译： EBOLAVIRUS和MARBURGVIRUS疫苗
公开(公告)号：WO2016097065A1
公开(公告)日：2016-06-23
申请号：PCT/EP2015/080108
申请日：2015-12-16
申请人： CUREVAC AG
发明人： RAUCH, Susanne , JASNY, Edith
IPC分类号： A61K39/00 , A61K39/12 , C12N15/67
CPC分类号： A61K39/12 , A61K2039/53 , A61K2039/54 , A61K2039/575 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N2760/14134 , C12N2760/14234 , C12N2830/50
摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein derived from the glycoprotein (GP) and/or the matrix protein 40 (VP40) and/or the nucleoprotein (NP) of a virus of the genus Ebolavirus or Marburgvirus or a fragment, variant or derivative thereof. Additionally, the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein derived from the glycoprotein (GP) and/or the matrix protein 40 (VP40) and/or the nucleoprotein (NP) of a virus of the genus Ebolavirus or Marburgvirus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Ebolavirus or Marburgvirus infections. The present invention further describes a method of treatment or prophylaxis of Ebolavirus or Marburgvirus infections using the mRNA sequence.
摘要翻译：本发明涉及一种mRNA序列，其包含编码来自病毒的糖蛋白（GP）和/或基质蛋白40（VP40）和/或核蛋白（NP）的至少一种抗原肽或蛋白质的编码区的埃博病毒属或马尔堡病毒或其片段，变体或衍生物。另外，本发明涉及包含多个mRNA序列的组合物，所述mRNA序列包含编码区，编码至少一种衍生自糖蛋白（GP）的抗原肽或蛋白质和/或基质蛋白40（VP40）和/或核蛋白（NP）或其片段，变体或衍生物。此外，它还公开了使用mRNA序列或包含多个mRNA序列的组合物用于制备药物组合物，特别是疫苗，例如疫苗。用于预防或治疗埃博病毒或马尔堡病毒感染。本发明还描述了使用mRNA序列治疗或预防埃博病毒或马尔堡病毒感染的方法。

5. 发明申请

WO2022200575A1 IMMUNOGENIC COMPOSITIONS 审中-公开
公开(公告)号：WO2022200575A1
公开(公告)日：2022-09-29
申请号：PCT/EP2022/057934
申请日：2022-03-25
申请人： GLAXOSMITHKLINE BIOLOGICALS SA , CUREVAC AG
发明人： GROBE, Hans Wolfgang , JASNY, Edith , MÜHE, Janine , VASSILEV, Ventzislav Bojidarov , LORIN, Clarisse , OUAKED, Nadia , MALLETT, Corey , ROUXEL, Ronan , BLAIS, Normand
IPC分类号： A61K45/06 , A61K31/7105 , A61K31/7115 , A61K39/12 , A61P31/16 , A61K2039/53 , A61K2039/55555 , A61K2039/575 , A61K2039/6068 , A61K9/0019 , A61K9/5123 , C12N2760/16134
摘要： The present invention relates to carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.

6. 发明申请

WO2017191258A9 INFLUENZA MRNA VACCINES 审中-公开
公开(公告)号：WO2017191258A9
公开(公告)日：2017-11-09
申请号：PCT/EP2017/060663
申请日：2017-05-04
申请人： CUREVAC AG
发明人： JASNY, Edith , RAUCH, Susanne , SCHMIDT, Kim Ellen , PETSCH, Benjamin , SLOBOD, Karen
IPC分类号： A61K39/12 , A61K39/145
摘要： The present invention relates to mRNA sequences usable as mRNA-based vaccines against infections with influenza viruses. Additionally, the present invention relates to a composition comprising the mRNA sequences and the use of the mRNA sequences or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of influenza virus infections. The present invention further describes a method of treatment or prophylaxis of infections with influenza virus using the mRNA sequences.
摘要翻译：本发明涉及可用作针对流感病毒感染的基于mRNA的疫苗的mRNA序列。此外，本发明涉及包含mRNA序列的组合物，以及用于制备药物组合物，特别是疫苗例如人类或动物的mRNA序列或组合物的用途。用于预防或治疗流感病毒感染。本发明进一步描述了使用mRNA序列治疗或预防流感病毒感染的方法。

7. 发明申请

WO2017081082A2 OPTIMIZED NUCLEIC ACID MOLECULES 审中-公开
标题翻译：优化的核酸分子
公开(公告)号：WO2017081082A2
公开(公告)日：2017-05-18
申请号：PCT/EP2016/077145
申请日：2016-11-09
申请人： CUREVAC AG
发明人： BAUMHOF, Patrick , RAUCH, Susanne , KOWALCZYK, Aleksandra , LUTZ, Johannes , JASNY, Edith , PETSCH, Benjamin , THESS, Andreas , SCHLAKE, Thomas , FOTIN-MLECZEK, Mariola , HEIDENREICH, Regina , LAZZARO, Sandra , DÖNER, Fatma , GROßE, Wolfgang
IPC分类号： C12N15/00 , A61K48/00
CPC分类号： C12N15/00 , A61K48/00 , A61K2039/53 , C07K2319/00
摘要： The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g. selected among nucleic acid moieties encoding a polypeptide element, such as a secretory signal peptide (SSP), a multimerization element (dimerization, trimerization, tetramerization and oligomerization), a virus like particle (VLP) forming element, a transmembrane element, a dendritic cell targeting element, an immunological adjuvant element, an element promoting antigen presentation; a 2A peptide; a peptide linker element, elements that extend protein half-life, and/or any other polypeptide or protein. Non-coding nucleic acid moieties may be selected e.g. from the group comprising 3'-UTR, 5'-UTR, IRES element, miRNA moiety, histone stem loop, poly(C) sequence, polyadenylation signal, polyA-sequence. The optimized nucleic acid molecule can further be characterized by the presence of at least one modified nucleoside. The versatility of the present invention allows for rational design of a large variety of different nucleic acid molecules with desired properties.
摘要翻译：本发明提供了优化的核酸分子，用于优化核酸分子的方法和优化的核酸分子的用途。提供了模块化设计原理，其适合于产生针对相应应用定制的核酸，特别是mRNA。本发明的核酸分子可以通过在核酸水平上多种组件的多种组合来获得。这样的核酸，例如可以通过组合一种或多种模块来定制mRNA，所述模块包含（i）编码感兴趣的多肽（例如可能产生治疗结果的蛋白质）的核酸部分和（ii）至少一种另外的编码或非编码核酸部分，例如（SSP），多聚化元件（二聚化，三聚化，四聚化和低聚化），病毒样颗粒（VLP）形成元件，跨膜元件，树突状细胞等的编码多肽元件的核酸部分靶向元件，免疫佐剂元件，促进抗原呈递的元件; 2A肽; 肽接头元件，延长蛋白质半衰期的元件，和/或任何其他多肽或蛋白质。可以选择例如非编码核酸部分。来自包含3'-UTR，5'-UTR，IRES元件，miRNA部分，组蛋白茎环，聚（C）序列，聚腺苷酸化信号，聚A序列的组。优化的核酸分子可以进一步通过存在至少一种修饰的核苷来表征。本发明的多功能性允许合理设计具有期望特性的多种不同核酸分子。

8. 发明申请

WO2019115635A1 FLAVIVIRUS VACCINE 审中-公开
公开(公告)号：WO2019115635A1
公开(公告)日：2019-06-20
申请号：PCT/EP2018/084607
申请日：2018-12-12
申请人： CUREVAC AG , SANOFI PASTEUR
发明人： BAUMHOF, Patrick , GROSSE, Wolfgang , JASNY, Edith , KRAMPS, Thomas , VOSS, Daniel , DANNENMAIER, Julia , LECOUTURIER, Valérie , GIRERD-CHAMBAZ, Yves
IPC分类号： A61K39/12 , C12N15/63 , A61P31/14
CPC分类号： A61K39/12 , A61K2039/53 , A61P31/14 , C12N2770/24111
摘要： The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptide, composition, in particular the first and second medical uses of the immunogenic composition according to the invention.

9. 发明申请

WO2019038332A1 BUNYAVIRALES VACCINE 审中-公开
公开(公告)号：WO2019038332A1
公开(公告)日：2019-02-28
申请号：PCT/EP2018/072675
申请日：2018-08-22
申请人： CUREVAC AG
发明人： PETSCH, Benjamin , JASNY, Edith
IPC分类号： C12N15/67 , C12N15/85
摘要： The present invention is directed to an artificial nucleic acid, particularly to an artificial RNA, and to polypeptides suitable for use in treatment or prophylaxis of an infection with a virus of the order Bunyavirales, particularly Severe fever with thrombocytopenia syndrome virus (SFTSV), Rift Valley fever virus (RVFV), or Crimean-Congo hemorrhagic fever virus (CCHFV), or a disorder related to such an infection. The present invention further concerns a Bunyavirales vaccine, particularly a SFTSV, RVFV, or CCHFV vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

10. 发明申请

WO2017191258A8 INFLUENZA MRNA VACCINES 审中-公开
公开(公告)号：WO2017191258A8
公开(公告)日：2017-11-09
申请号：PCT/EP2017/060663
申请日：2017-05-04
申请人： CUREVAC AG
发明人： JASNY, Edith , RAUCH, Susanne , SCHMIDT, Kim Ellen , PETSCH, Benjamin , SLOBOD, Karen
IPC分类号： A61K39/12 , A61K39/145
摘要： The present invention relates to mRNA sequences usable as mRNA-based vaccines against infections with influenza viruses. Additionally, the present invention relates to a composition comprising the mRNA sequences and the use of the mRNA sequences or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of influenza virus infections. The present invention further describes a method of treatment or prophylaxis of infections with influenza virus using the mRNA sequences.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式